Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 4,285 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $25.00, for a total value of $107,125.00. Following the sale, the director owned 25,107 shares in the company, valued at approximately $627,675. This represents a 14.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Enliven Therapeutics Trading Down 3.7%

Shares of NASDAQ ELVN traded down $0.97 during mid-day trading on Monday, hitting $25.03. The company had a trading volume of 1,373,161 shares, compared to its average volume of 2,697,186. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.98. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41. The stock’s 50-day moving average price is $19.07 and its 200-day moving average price is $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ELVN. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. grew its position in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Enliven Therapeutics by 4.8% during the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock valued at $691,000 after purchasing an additional 1,540 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.